Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_2
3
38%
Ph not_applicable
1
13%
Ph early_phase_1
1
13%
Ph phase_4
2
25%

Phase Distribution

1

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Early Phase 1First-in-human
1(14.3%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 4Post-market surveillance
2(28.6%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(3)
Terminated(1)
Other(4)

Detailed Status

unknown4
Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (14.3%)
Phase 23 (42.9%)
Phase 42 (28.6%)
N/A1 (14.3%)

Trials by Status

completed338%
unknown450%
terminated113%

Recent Activity

Clinical Trials (8)

Drug Details

Intervention Type
OTHER
Total Trials
8